Provost & Chief Academic Officer of Howard University brings scientific experience and new perspectives on the consequences of sickle cell disease Fort Collins, CO, June 21, 2022 – Cetya Therapeutics, Inc. today announced the addition of Dr. Anthony Wutoh, Provost and Chief Academic Officer of Howard University, to its Board of Directors.   Dr. Wutoh received […]

$170,000 Colorado Grant will advance Cetya’s novel targeted HDAC inhibitor program.

$240,000 Grant will allow evaluation of Cetya’s HDAC inhibitors for treatment of sickle cell disease.

$220,000 Round includes Canadian firm InSynchrony Ventures Inc Proceeds will advance oncology drug development. Fort Collins, CO, May 8, 2017 – Cetya Therapeutics, Inc. announces the closing of a $220,000 seed round financing. Funding was provided by private investors, including company insiders, and InSynchrony Ventures Inc (InSynchrony), a strategic investor located in Montreal. Dr. Dean […]